Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
US7829724B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 11, 2006 |
| Grant date | Nov 9, 2010 |
| Priority date | — |
| Expiry date | Jul 28, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.